Here are the 10-K annual reports from BioLife Solutions Inc. (BLFS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow BLFS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BLFS filings page.
BioLife Solutions, Inc. filed Amendment No. 1 to its 2025 annual report to add detailed Part III information on directors, executive officers, governance and compensation instead of filing a proxy. The company reports 2025 revenue of $96.2 million, up from $74.6 million in 2024, and highlights focus on biopreservation media and cell processing tools.
BioLife completed the acquisition of PanTHERA CryoSolutions for about $11.5 million in cash plus $4.5 million in stock and divested SAVSU Technologies, generating about $23.3 million in cash. Named executive officer bonuses were tied to revenue, adjusted EBITDA margin, a clean 2025 annual report with no material weaknesses, and NetSuite MRP implementation, resulting in 2025 payouts at roughly 98% of target.
BioLife Solutions, Inc. filed its annual report describing a focused life sciences business supplying bioproduction tools for the cell and gene therapy industry. The company develops and manufactures biopreservation media, human platelet lysate, closed-system containers, and automated thawing and cell-processing devices used across CGT workflows.
BioLife has reshaped its portfolio through several divestitures of freezer, cold-chain logistics, and shipping businesses, while acquiring the remaining 90% of PanTHERA CryoSolutions to add next‑generation cryopreservation technology. Revenue is concentrated in the United States, and a small number of customers and CryoStor products drive a large share of sales.
The report highlights extensive risk factors, including heavy competition, reliance on key customers and suppliers, potential product defects, evolving global regulations, cybersecurity and AI-related risks, and the possibility of goodwill and intangible asset impairments. Management also emphasizes its patent portfolio, cGMP manufacturing, quality systems, and efforts to retain specialized talent to support growth.